Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward

Targeting the cell cycle has become a focus of cancer research bearing impressive results with the introduction of CDK4/6 inhibitors in the treatment of ER-positive/HER2-negative breast cancers. However, no definitive benefit in other cancers has been observed. In gastrointestinal cancers, despite p...

Full description

Saved in:
Bibliographic Details
Main Author: Ioannis A. Voutsadakis
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Current Issues in Molecular Biology
Subjects:
Online Access:https://www.mdpi.com/1467-3045/47/6/454
Tags: Add Tag
No Tags, Be the first to tag this record!